• Price (USD)10.06
  • Today's Change-0.540 / -5.09%
  • Shares traded1.07m
  • 1 Year change-66.92%
  • Beta1.8750
Data delayed at least 15 minutes, as of Dec 01 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

  • Revenue in USD (TTM)25.64m
  • Net income in USD-201.13m
  • Incorporated2013
  • Employees264.00
  • Location
    Editas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
  • Phone+1 (617) 401-9000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.editasmedicine.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Allovir Inc0.00-188.52m699.65m107.00--2.75-----2.79-2.790.002.730.00----0.00-61.79---66.69--------------0.00-------146.42------
Exscientia PLC (ADR)43.28m-83.59m700.41m287.00--1.08--16.18-0.6902-0.69020.35925.270.0741--81.49150,788.70-14.32---15.98--32.57---193.15--9.08--0.0123--182.87---120.94------
Alector Inc133.17m-133.96m702.14m269.00--2.77--5.27-1.63-1.661.623.060.1575--32.98640,245.20-15.84-22.06-19.17-25.83-----100.59-148.38----0.00--881.54246.2780.90--7.61--
Allakos Inc0.00-371.33m702.93m192.00--2.04-----6.76-6.760.004.040.00----0.00-71.43-32.18-76.45-33.39------------0.00-------75.83--169.43--
Cerus Corporation187.08m-38.27m709.68m294.00--9.70--3.79-0.2184-0.21841.070.41220.86142.607.40636,333.30-17.65-37.07-28.11-52.3759.9561.16-20.48-61.351.44-5.490.4849--39.6232.359.16--10.08--
Merus NV45.63m-63.64m710.75m121.00--2.38--15.58-1.45-1.451.056.450.1184--15.56377,099.20-16.51-24.71-20.04-29.16-----139.48-178.24----0.00--64.0077.6421.86--9.66--
iTeos Therapeutics Inc454.23m261.07m716.84m94.002.961.132.741.586.806.8011.9617.830.5343--90.914,832,224.0030.71--49.06------57.48------0.00------594.27------
POINT Biopharma Global Inc0.00-79.17m719.44m72.00--2.29-----0.8713-0.87130.002.970.00----0.00-26.26---27.39--------------0.00-------243.25------
Invitae Corp519.97m-3.21bn721.40m2.30k--4.54--1.39-13.84-13.842.250.65420.146513.897.05173,323.30-90.50-19.73-94.07-20.7519.1332.19-617.65-121.686.18-14.590.9096--64.6879.0137.06--36.32--
Theravance Biopharma Inc51.64m-82.19m724.86m158.00--1.51--14.04-1.1011.250.68627.130.0885--3.67326,854.40-14.09-50.90-17.15-62.74-----159.16-439.62----0.00---23.032.6028.27--9.79--
Editas Medicine Inc25.64m-201.13m728.89m264.00--1.76--28.42-2.93-2.930.37416.030.0411--138.2497,136.37-32.23-28.88-34.83-32.06-----784.32-368.55----0.00---71.8533.37-65.98--17.96--
Aurinia Pharmaceuticals Inc129.00m-115.46m729.02m300.00--1.72--5.65-0.8297-0.82970.92392.980.30410.21445.00429,996.70-27.22-35.60-30.03-37.8196.29---89.50-523.0310.40--0.00---9.00204.93-76.24--126.82--
ANI Pharmaceuticals Inc283.08m-69.20m732.64m601.00--2.35--2.59-4.48-4.4818.0019.260.46811.732.29471,018.30-11.21-1.35-13.00-1.6451.8360.08-23.95-3.092.62-2.160.4599--3.6710.94-89.79---10.95--
Collegium Pharmaceutical Inc361.68m-42.84m734.22m152.00--3.7510.462.03-1.26-1.2610.615.840.37234.962.102,379,441.00-4.41-2.13-6.80-3.8943.7948.14-11.84-3.220.82160.49030.7858---10.69176.57167.33---8.17--
CTI BioPharma Corp32.87m-112.32m763.90m121.00------23.24-1.09-1.090.3074-0.13270.2925----271,611.60-99.98-82.10-169.44-126.5592.86---341.77-475.653.22-9.391.18-------86.67------
Agenus Inc89.90m-214.70m764.54m441.00------8.50-0.7998-0.79980.3333-0.06910.2075--5.88203,854.90-51.73-63.37-82.84-123.7195.82---249.34-98.76---3.088.30--235.3467.2886.67--21.98--
Data as of Dec 01 2022. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD

Institutional shareholders

39.39%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20226.61m9.62%
SSgA Funds Management, Inc.as of 30 Sep 20226.35m9.24%
BlackRock Fund Advisorsas of 30 Sep 20225.42m7.89%
Millennium Management LLCas of 30 Sep 20221.88m2.74%
PFM Health Sciences LPas of 30 Sep 20221.28m1.86%
Geode Capital Management LLCas of 30 Sep 20221.26m1.83%
Capital Research & Management Co. (World Investors)as of 30 Sep 20221.10m1.60%
JPMorgan Asset Management (UK) Ltd.as of 30 Sep 20221.09m1.59%
Two Sigma Advisers LPas of 30 Sep 20221.08m1.57%
Two Sigma Investments LPas of 30 Sep 20221.01m1.47%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.